ArticleEuropean journal of pediatrics2025
Insulin-like growth factor 1 as a diagnostic marker of progressive central precocious puberty: a prospective study.
Article in European journal of pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Central precocious puberty (CPP) diagnosis often requires invasive GnRH stimulation tests. Our purpose was to determine whether the IGF-1 and IGF-1 SDSs are reliable predictors of progressive CPP. This was a prospective study including 82 girls under 8 years of age. The participants were divided into CPP (n = 39), NP-CPP and IT (n = 26), and control groups (n = 17). Anthropometric measurements, Tanner staging, bone age, pelvic ultrasound, and serum IGF1 and IGF1-SDS level measurements were performed. GnRH stimulation tests confirmed CPP cases. The mean IGF1 and IGF1-SDS levels were significantly greater in CPP patients (270.15 ng/mL; 1.943 SDS) than in NP-CPP patients (174.12 ng/mL; 0.788 SDS) and controls (139.28 ng/mL; 0.208 SDS) (p < 0.001). Multivariate logistic regression analysis confirmed that IGF1 (OR = 1.025, 95% CI 1.010-1.040) and IGF1-SDS (OR = 8.721, 95% CI 2.624-28.986) were significant predictors of CPP. ROC analysis revealed an AUC of 0.837 for IGF1 (95% CI 0.738-0.935) and 0.862 for IGF1-SDS (95% CI 0.771-0.953). The cut-off values of 231 ng/mL for IGF1 (71.8% sensitivity, 97.7% specificity) and 1.44 for IGF1-SDS (79.5% sensitivity, 90.7% specificity) demonstrated good accuracy (82.2% and 77.8%, respectively).
conclusionIGF1-SDS, and absolute IGF1, are promising effective noninvasive diagnostic markers for distinguishing CPP from nonprogressive precocious puberty. Due to its high specificity IGF1 values above 1.44, SDS may significantly increase the post-test probability of CPP, potentially avoiding invasive GnRH stimulation tests. These findings support the integration of IGF1 measurements into the initial diagnostic approach for girls presenting with early pubertal signs. WHAT IS KNOWN: • Central precocious puberty (CPP) often requires invasive GnRH stimulation tests. • IGF1 levels rise during puberty and reflect growth and pubertal progression. WHAT IS NEW: • This prospective study suggests IGF1-SDS >1.44 as accurate cut-off for progressive CPP via the IMMULITE assay. • IGF1-SDS show high specificity and diagnostic accuracy, supporting its use in the initial diagnostic approach for girls presenting with early pubertal signs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.